Relief Therapeutics Announces CEO Transition
Relief Therapeutics Announces CEO Transition
GENEVA, SWITZERLAND / ACCESSWIRE / November 22, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its current chief executive officer (CEO), Jack Weinstein, will be stepping down as part of a leadership transition. The company is pleased to announce that Michelle Lock, a highly experienced pharmaceutical executive and current independent member of Relief's Board of Directors, will be assuming the role of CEO on an interim basis.
瑞士日內瓦/ACCESSWIRE /2023 年 11 月 22 日/致力於爲特定特殊疾病、未被滿足的疾病和罕見疾病提供創新治療方案的生物製藥公司救濟療法控股有限公司(SIX: RLLF)(OTCQB: RLFTF)(OTCQB: RLFTY)(Relief,或公司)今天宣佈,其現任首席執行官(首席執行官)傑克·溫斯坦將辭職領導層過渡。公司很高興地宣佈,經驗豐富的製藥業高管、現任救濟董事會獨立成員米歇爾·洛克將臨時擔任首席執行官一職。
"Michelle has been an active and insightful member of our Board of Directors. Her deep understanding of our organization and her extensive leadership experience in both biotech and big pharma settings make her an ideal leader for Relief. We are excited to have Michelle continue on the Board of Directors and step in as our new CEO." said Raghuram (Ram) Selvaraju, Chairman of the Board of Directors. "I want to extend our gratitude to Jack for his dedication and the important contributions he made over the years." added Dr. Selvaraju.
“Michelle一直是我們董事會中一位活躍而富有洞察力的成員。她對我們組織的深刻理解以及在生物技術和大型製藥領域的豐富領導經驗,使她成爲Relief的理想領導者。我們很高興米歇爾能繼續擔任董事會成員並出任新任首席執行官。” 董事會主席拉古拉姆(Ram)Selvaraju說。塞爾瓦拉尤博士補充說:“我要感謝傑克的奉獻精神和多年來所做的重要貢獻。”
Ms. Lock previously held executive roles as chief operating officer of Covis Pharma Group and senior vice president and head of Europe and International at Acceleron Pharma Inc. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience and spent 24 years with Bristol-Myers Squibb. Her appointment as interim CEO of Relief is effective immediately.
洛克女士此前曾擔任Covis Pharma Group首席運營官和Acceleron Pharma Inc.的高級副總裁兼歐洲和國際負責人。她擁有近30年的生物製藥戰略、運營和商業化經驗,並在百時美施貴寶工作了24年。她被任命爲Relief臨時首席執行官的任命立即生效。
In response to her appointment, Ms. Lock commented, "I am honored to step into the role of CEO of Relief. This company has a strong legacy of bringing significant value to patients, and I am excited to lead our talented team as we continue to advance our pipeline. I am committed to driving our company on a path of innovation and enhanced patient impact."
洛克女士在回應她的任命時評論說:“我很榮幸擔任Relief首席執行官一職。這家公司在爲患者帶來巨大價值方面有着悠久的傳統,我很高興能領導我們才華橫溢的團隊,繼續推進我們的產品線。我致力於推動我們公司走上創新和增強患者影響力的道路。”
The Company is looking forward to a new chapter under Michelle Lock's leadership.
公司期待在米歇爾·洛克的領導下開啓新的篇章。
ABOUT RELIEF THERAPEUTICS
關於救濟療法
Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics' portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic and TEHCLO platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners. Relief Therapeutics' mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Monza, Italy. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website or follow Relief Therapeutics on LinkedIn and Twitter.
Relief Therapeutics是一家處於商業階段的生物製藥公司,致力於推進治療模式,提高療效、安全性和便利性,從而使患有特定特殊疾病和罕見疾病的患者的生活受益。Relief Therapeutics的產品組合平衡地組合了已上市的創收產品、我們專有的全球專利Physiomimic和TEHCLO平台技術,以及由專注於三個核心治療領域的風險緩解資產組成的有針對性的臨床開發渠道:罕見代謝性疾病、罕見皮膚病和罕見呼吸道疾病。此外,Relief Therapeutics正在通過許可和分銷合作伙伴將幾種傳統產品商業化。Relief Therapeutics的使命是爲罕見病患者提供治療救濟,由一支由經驗豐富、經驗豐富的生物製藥行業領導者組成的國際團隊正在推進,他們擁有廣泛的研究、開發和罕見病專業知識。Relief Therapeutics總部位於日內瓦,並在瑞士巴萊爾納、德國美因河畔奧芬巴赫和意大利蒙扎設有辦事處。Relief Therapeutics在瑞士證券交易所上市,代碼爲RLF,在美國的OTCQB上市,股票代碼爲RLFTF和RLFTY。欲了解更多信息,請訪問我們的網站或在 LinkedIn 和 Twitter 上關注 Relief Therapeutics。
CONTACT:
聯繫:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
救濟治療控股有限公司
傑里米·梅寧
首席財務官
contact@relieftherapeutics.com
Disclaimer
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief's filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief Therapeutics. Copies of Relief Therapeutics' filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief Therapeutics does not undertake any obligation to update the information contained herein, which speaks only as of this date.
免責聲明
本新聞稿包含前瞻性陳述。前瞻性陳述涉及已知和未知的風險和不確定性,這可能導致Relief的實際業績、財務狀況、業績或成就與此類前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異。許多因素,包括Relief向瑞士證券交易所證券交易所和美國證券交易委員會(SEC)提交的文件中描述的因素,可能會對Relief Therapeutics產生不利影響。Relief Therapeutics向美國證券交易委員會提交文件的副本可在美國證券交易委員會EDGAR數據庫www.sec.gov上查閱。Relief Therapeutics不承擔任何義務更新此處包含的信息,該信息僅代表截至該日期。
SOURCE: RELIEF THERAPEUTICS Holding SA
來源:救濟療法控股有限公司
譯文內容由第三人軟體翻譯。